Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Surg Oncol. 2012 Oct;19(11):3460-4. doi: 10.1245/s10434-012-2436-x. Epub 2012 Jun 14.
The influence of body mass index (BMI) on the outcome of patients with colorectal cancer (CRC) is largely unknown, particularly in an Asian population. Therefore, we investigated the influence of BMI on survival of patients who underwent surgical treatment for CRC in Korean population.
This prospective cohort study included CRC patients who underwent surgery between June 2003 and May 2005. Study participants were divided into two BMI groups: normal weight (<23 kg/m(2)) and overweight (≥23 kg/m(2)).
A total of 509 CRC patients were included in this study. Of these, 318 patients (62.5%) were male, and the mean ± SD age was 59.1 ± 11.3 years. Two hundred eighteen patients (42.8%) were included in the normal-weight group and 291 (57.2%) were included in the overweight group. During a follow-up of 62.8 ± 27.2 months, 100 (19.6%) of the 509 eligible patients died, and 72 (15.0%) of 479 experienced recurrence. The overall survival of overweight group was more favorable compared with that of the normal-weight group (P = 0.001), while there was no significant difference in recurrence (P = 0.735). Compared with the normal-weight group, the hazard ratios of death and recurrence, respectively, were 0.615 (95% confidence interval 0.408-925; P = 0.020) and 0.992 (95% confidence interval 0.613-1.604; P = 0.973) for the overweight group.
Overweight is not associated with an increased risk of cancer recurrence but rather is associated a favorable overall survival in Asian CRC patients undergoing surgery.
体重指数（BMI）对结直肠癌（CRC）患者结局的影响尚不清楚，尤其在亚洲人群中。因此，我们研究了 BMI 对韩国人群 CRC 手术患者生存的影响。
这是一项前瞻性队列研究，纳入 2003 年 6 月至 2005 年 5 月间接受手术治疗的 CRC 患者。研究对象分为两组：正常体重（<23kg/m²）和超重（≥23kg/m²）。
本研究共纳入 509 例 CRC 患者，其中 318 例（62.5%）为男性，平均年龄（±标准差）为 59.1±11.3 岁。218 例（42.8%）患者为正常体重，291 例（57.2%）为超重。随访 62.8±27.2 个月期间，509 例患者中有 100 例（19.6%）死亡，72 例（15.0%）复发。超重组患者的总生存情况优于正常体重组（P=0.001），但两组间复发情况无显著差异（P=0.735）。与正常体重组相比，超重组死亡和复发的风险比分别为 0.615（95%可信区间 0.408-925；P=0.020）和 0.992（95%可信区间 0.613-1.604；P=0.973）。
超重与 CRC 患者术后癌症复发风险增加无关，而是与总体生存情况改善相关。
